Evidence, Efficasy and Safety of the Chondroprotective Parapharmaceuticals in Treatment of the Early Stages of Osteoarthritis


Oleksandr Burianov
Liudmyla Khimion
Taras Omelchenko
Myroslav Vakulych


Osteoarthritis (OA) is the most common joint disease that significantly affects the patients’ quality of life and requires significant medical and social investments for treatment and rehabilitation. There are no therapeutic agents which would be able to regenerate lost or damaged hyaline cartilage.

The objective: to assess the efficacy and safety of the chondroprotective parapharmaceutical agent Flexogial in the complex treatment of patients with initial stages of the knee ОА.

Materials and methods. 12-weeks study was conducted with the participation of 60 patients with knee OA aged 53,7±2,9 years, women – 36 (60%), men – 24 (40%) with the initial stages of the disease (I–II radiological stage). The main clinical group consisted of 30 patients who took the chondroprotective complex agent Flexogial 15 ml once a day; the comparison group included 30 patients who were administered glucosamine sulfate 1500 mg in a monopreparation taken once a day. Efficacy of the treatment was evaluated using the VAS scale, Tegner’s scale, Lisholm scale at the beginning of treatment, after 6 and 12 weeks in dynamics with subsequent statistical processing of the results.

Results. The study demonstrated better indicators of functional activity and less pain intensity in the affected joints in patients of the main group who took the parapharmaceutical agent Flexogial compared to the group of patients who took glucosamine monopreparation with the same number of registered adverse events in both groups of patients (5%).

Conclusions. The results of the presented clinical study proved the advantage of use of the combined chondroprotective drinking complex Flexogial in comparison with the monopharmaceutical preparation glucosamine sulfate in the treatment of patients with early stages knee OA in terms of the effect on the intensity of pain and improvement in the parameters of the functional activity of patients after 6 and 12 weeks with the same frequency of registered adverse events.


How to Cite
Burianov, O., Khimion, L., Omelchenko, T., & Vakulych, M. (2021). Evidence, Efficasy and Safety of the Chondroprotective Parapharmaceuticals in Treatment of the Early Stages of Osteoarthritis. Family Medicine, (2-3), 34–42. https://doi.org/10.30841/2307-5112.2-3.2021.240762
For practicing physicians
Author Biographies

Oleksandr Burianov, Bogomolets National Medical University

Oleksandr A. Burianov,

Head of Department of Traumatology and Orthopedics

Liudmyla Khimion, Shupyk National Healthcare University of Ukraine

Liudmyla V. Khimion,

Department of Family Medicine

Taras Omelchenko, Bogomolets National Medical University

Taras M. Omelchenko,

Department of Traumatology and Orthopedics

Myroslav Vakulych, Bogomolets National Medical University

Myroslav V. Vakulych,

Department of Traumatology and Orthopedics


Asari A, Kanemitsu T, Kurihara H. Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. J Biol Chem. 2010;285:24751–8. DOI: 10.1074/jbc.M110.104950.

Asserin J, Lati E, Shioya T, Prawitt J. The effect of oral collagen peptide supplementation on skin moisture and the dermal collagen network: evidence from an ex vivo model and randomized, placebo-controlled clinical trials. J Cosmet Dermatol. 2015;14(4):291–301. DOI: 10.1111/jocd.12174.

Bruyère O, Zegels B, Leonori L, Rabenda V, Janssen A, Bourges C, Reginster JY. Effect of collagen hydrolysate in articular pain: a 6-month randomized, double-blind, placebo controlled study. Complement Ther Med. 2012 Jun;20(3):124-30. DOI: 10.1016/j.ctim.2011.12.007.

Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 1995;45(8):918–25.

Dar Q.A., Schott E.M., Catheline S.E., Maynard R.D., Liu Z., Kamal F., Farnsworth C. W., Ketz J.P., Mooney R.A., Hilton M.J., Jonason J.H., Prawitt J., & Zuscik M.J. (2017). Daily oral consumption of hydrolyzed type 1 collagen is chondroprotective and anti-inflammatory in murine posttraumatic osteoarthritis. PloS one, 12(4), e0174705. DOI: org/10.1371/journal.pone.0174705

Essex MN, O’Connell MA, Behar R, Bao W. Efficacy and safety of non-steroidal anti-inflammatory drugs in Asian patients with knee osteoarthritis: summary of a randomized, placebo-controlled study. Int J Rheum Dis. 2016;19(3):262–70.

Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343–55.

FDA. Database of Select Committee on GRAS Substances (SCGRAS) Opinion: Gelatin 1975. updated 09/29/2015

Glyn-Jones S, Palmer AJ, Agricola R, et al. Osteoarthritis. Lancet. 2015;386(9991):376–87.

Guillerminet F, Beaupied H, Fabien-Soule V, Tome D, Benhamou CL, Roux C, et al. Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. Bone. 2010;46(3):827–34. DOI 10.1016/j.bone.2009.10.035.

Hays N.P., Kim H., Wells A.M., Kajkenova O., Evans W.J. Effects of whey and fortified collagen hydrolysate protein supplements on nitrogen balance and body composition in older women. J. Am. Diet. Assoc. 2009;109:1082–7. DOI: 10.1016/j.jada.2009.03.003.

Hisada N, Satsu H, Mori A, Totsuka M, Kamei J, Nozawa T, et al. Low-Molecular-Weight Hyaluronan Permeates through Human Intestinal Caco-2 Cell Monolayers via the Paracellular Pathway. Biosci Biotechnol Biochem. 2008;72:1111–4. DOI: 10.1271/bbb.70748.

Honvo, G., Lengelé, L., Charles, A. et al. Role of Collagen Derivatives in Osteoarthritis and Cartilage Repair: A Systematic Scoping Review With Evidence Mapping. Rheumatol Ther 7:703–40 (2020). DOI: 10.1007/s40744-020-00240-5.

http://pathways.nice.org.uk/pathways/osteoarthritis NICE Pathway last updated: 04 June 2020.

Ichikawa S, Morifuji M, Ohara H, Matsumoto H, Takeuchi Y, Sato K. Hydroxyproline-containing dipeptides and tripeptides quantified at high concentration in human blood after oral administration of gelatin hydrolysate. Int J Food Sci Nutr. 2010;61(1):1–9.

Jiang J-X, Yu S, Huang Q-R, Zhang X-L, Zhang C-Q, Zhou J-L, et al. Collagen peptides improve knee osteoarthritis in elderly women: A 6-month randomized, double-blind, placebo-controlled study. Agro food industry Hi Tech. 2014;25(2):19–23.

Kurihara H, Kawada C, Yoshida H, Kimura M, Kanemitsu T, Masuda Y, et al. Absorption and effect on the skin of oral hyaluronan. 2014.

Lotz M, Martel-Pelletier J, Christiansen C, et al. Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis. 2013;72(11):1756–63.

McAlindon TE, Nuite M, Krishnan N, Ruthazer R, Price LL, Burstein D, et al. Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. Osteoarthritis Cartilage. 2011;19(4):399–405. DOI: 10.1016/j.joca.2011.01.001.

Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165.

Oe M., Tashiro, T., Yoshida, H., Nishiyama, H., Masuda, Y., Maruyama, K., Koikeda, T., Maruya, R., & Fukui, N. (2016). Oral hyaluronan relieves knee pain: a review. Nutrition journal, 15, 11. DOI: org/10.1186/s12937-016-0128-2.

Olivier Bruyerea et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), Seminars in Arthritis and Rheumatism 000 (2019) 1/14.

Osteoarthritis: Rapid Evidence Review Mark H. Ebell, MD, MS, University of Georgia College of Public Health, Athens, Georgia.

Persiani S, Rotini R, Trisolino G, et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil. 2007;15(7):764–72.

Raabe O, Reich C, Wenisch S, Hild A, Burg-Roderfeld M, Siebert HC, et al. Hydrolyzed fish collagen induced chondrogenic differentiation of equine adipose tissue-derived stromal cells. Histochem Cell Biol. 2010;134(6):545–54. DOI: 10.1007/s00418-010-0760-4.

Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, Largo R, Herrero-Beaumont G. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis: a six-month multicenter, randomized, double-blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol. 2017;69(1):77–85.

Sharon L. Kolasinskiet al. 2019 American College of Rheumatology / Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee, Arthritis Care & Research. 2020;72(2):149–62.

Shigemura Y, Kubomura D, Sato Y, Sato K. Dose-dependent changes in the levels of free and peptide forms of hydroxyproline in human plasma after collagen hydrolysate ingestion. Food Chem. 2014;159:328–32. DOI: 10.1016/j.foodchem.2014.02.091.

Van Vijven JP, Luijsterburg PA, Verhagen AP, van Osch GJ, Kloppenburg M, Bierma-Zeinstra SM. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. Osteoarthritis Cartilage. 2012;20(8):809–21. DOI: 10.1016/j.joca.2012.04.008.

Varani J., Dame M.K., Rittie L., Fligiel S.E.G., Kang S., Fisher G.J., Voorhees J.J. Decreased collagen production in chronologically aged skin: Roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am. J. Pathol. 2006;168:1861-1868. DOI: 10.2353/ajpath.2006.051302.

Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthr Cartil. 1998;6 Suppl A:37–8.

Zegels B, Crozes P, Uebelhart D, Bruyere O, Reginster JY. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil. 2013;21(1):22–7.

Zeggini E, et al. Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet. 2012;380(9844):815–23.

Bur’ianov O.A., Omelchenko T.M., Mikhnevych O.E.. Osteoarthritis: genesis, diagnosis, treatment. K.: Lenvit, 2009:203: il. Bibliogr.: 175–200.

Osadchii O. Osteoarthritis, anky-losing spondylitis and psoriasis: new in treatment. Ukrainian medical journal. 2019;4(1):13–5. Available from: http://nbuv.gov.ua/UJRN/UMCh_2019_4%281%29_5